Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961337 | 0.92 | TRPM5 (0.59) | GAATRPM5HPGD | |
| SCHEMBL7961336 | 0.86 | GAA (0.59) | GAA | |
| SCHEMBL7974779 | 0.85 | GAA (0.54) | GAA | |
| SCHEMBL7974686 | 0.85 | GAA (0.54) | GAA | |
| SCHEMBL7967214 | 0.85 | GAA (0.84) | GAAHPGDMAPT | |
| SCHEMBL7965165 | 0.85 | GAA (0.57) | GAALMNAMAPT | |
| SCHEMBL7973012 | 0.83 | — | — | |
| SCHEMBL13491767 | 0.83 | — | — | |
| SCHEMBL7961035 | 0.82 | — | — | |
| SCHEMBL13491781 | 0.82 | GAA (0.51) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118711-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9783521-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20140038951-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2010017236-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118711-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | GAA 64/4885LMNA 3928/4885SMN1; SMN2 527/4885 |
| US-20140038951-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | GAA 64/4885LMNA 3928/4885SMN1; SMN2 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.